デフォルト表紙
市場調査レポート
商品コード
1667889

記憶力強化薬市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、投与経路別、流通チャネル別、地域別、競合別、2020～2030年

Memory Enhancement Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 183 Pages
納期
2～3営業日
カスタマイズ可能
記憶力強化薬市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、投与経路別、流通チャネル別、地域別、競合別、2020～2030年
出版日: 2025年02月28日
発行: TechSci Research
ページ情報: 英文 183 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

世界の記憶力強化薬市場は、2024年に73億2,000万米ドルと評価され、2030年には99億5,000万米ドルに達し、予測期間中に5.21%のCAGR（複合年間成長率）で成長すると予測されています。

この市場は、より広範な認知健康・神経学セグメントのサブセットであり、主に記憶力、認知機能、脳の健康全般の改善を目的とした医薬品やサプリメントに焦点を当てています。市場拡大の背景には、認知障害の有病率の上昇、人口の高齢化、認知機能の向上への注目の高まりがあります。

市場概要
予測期間 2026～2030年
市場規模：2024年 73億2,000万米ドル
市場規模：2030年 99億5,000万米ドル
CAGR：2025～2030年 5.21%
急成長セグメント コリンエステラーゼ阻害剤
最大市場 北米

市場促進要因

1.人口の高齢化

主要市場課題

1.規制と安全性への懸念

主要市場動向

1.認知健康とウェルネスへの関心の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の記憶力強化薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤クラス別（コリンエステラーゼ阻害剤、スマートドラッグと認知機能向上剤、ビタミンとサプリメント、その他）
    • 投与経路別（経口、注射、局所）
    • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
    • 地域別
    • 企業別（2024年）
  • 市場マップ

第6章 北米の記憶力強化薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の記憶力強化薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋の記憶力強化薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の記憶力強化薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの記憶力強化薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収（該当する場合）
  • 製品の発売（該当する場合）

第13章 ポーターのファイブフォース分析

  • 産業内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Pfizer Inc.
  • UCB S.A.
  • Takeda Pharmaceutical Company Limited
  • SANOCHEMIA Pharmazeutika GmbH
  • AbbVie Inc.
  • Novartis AG
  • Alkem Laboratories Ltd.
  • Intas Pharmaceutical Ltd.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 19159

The global Memory Enhancement Drugs Market was valued at USD 7.32 billion in 2024 and is projected to reach USD 9.95 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.21% during the forecast period. This market is a subset of the broader cognitive health and neurology sectors, primarily focusing on pharmaceuticals and supplements aimed at improving memory, cognitive function, and overall brain health. The market's expansion is driven by the rising prevalence of cognitive disorders, an aging population, and a growing focus on cognitive well-being.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.32 Billion
Market Size 2030USD 9.95 Billion
CAGR 2025-20305.21%
Fastest Growing SegmentCholinesterase Inhibitors
Largest MarketNorth America

Key Market Drivers

1. Aging Population

The aging global population is a significant driver in the memory enhancement drugs market. As individuals age, they become more susceptible to cognitive decline and neurodegenerative diseases such as Alzheimer's and dementia, increasing the demand for memory-enhancing solutions.

  • Rising Proportion of Elderly: The demographic shift toward an aging population is a key factor propelling the demand for memory enhancement drugs. This shift is attributed to lower birth rates and higher life expectancy. According to the World Health Organization, by 2050, the global population aged 60 and above is expected to double to 2.1 billion, with the number of people aged 80 and older tripling from 2020 to 2050, reaching 426 million.

Key Market Challenges

1. Regulatory and Safety Concerns

A significant challenge facing the market is the lack of sufficient scientific evidence supporting the long-term safety and efficacy of many memory enhancement drugs. Numerous products, especially those marketed as over-the-counter supplements or off-label drugs, do not undergo rigorous clinical trials to validate their claims.

  • Regulatory Gaps: In many regions, inadequate regulation allows certain products to enter the market without comprehensive testing or quality control. This exposes consumers to potential risks from ineffective or harmful substances. The lack of sufficient regulation also results in insufficient consumer awareness regarding potential risks, leading to misuse or adverse effects.

Key Market Trends

1. Growing Focus on Cognitive Health and Wellness

There is a noticeable shift towards preventive healthcare, with an increasing emphasis on maintaining cognitive health throughout life. As people become more aware of the importance of cognitive function for overall well-being, they are actively seeking ways to optimize memory, mental clarity, and brain health at all stages of life. This shift has led to greater interest in both traditional and innovative methods for enhancing cognitive performance.

  • A 2021 study involving 44 healthy participants aged 18 to 36 showed that those who took prucalopride performed significantly better in memory tests compared to a placebo group. Functional MRI scans revealed enhanced brain activity, particularly in regions related to memory, including the hippocampus and the right angular gyrus.

Key Market Players

  • Pfizer Inc.
  • UCB S.A.
  • Takeda Pharmaceutical Company Limited
  • SANOCHEMIA Pharmazeutika GmbH
  • AbbVie Inc.
  • Novartis AG
  • Alkem Laboratories Ltd.
  • Intas Pharmaceutical Ltd.
  • Otsuka Holdings Co., Ltd.

Market Segmentation

The Global Memory Enhancement Drugs Market is segmented as follows:

1. By Drug Class

  • Cholinesterase Inhibitors
  • Smart Drugs and Cognitive Enhancers
  • Vitamins and Supplements
  • Others

2. By Route of Administration

  • Oral
  • Injectable
  • Topical

3. By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

4. By Region

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

The report provides detailed analysis of the major players in the global Memory Enhancement Drugs Market.

Available Customizations

TechSci Research offers customization options for this report, including the following:

  • Company Information: In-depth profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Memory Enhancement Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Cholinesterase Inhibitors, Smart Drugs and Cognitive Enhancers, Vitamins and Supplements, Others)
    • 5.2.2. By Route of Administration (Oral, Injectable, Topical)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Memory Enhancement Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Memory Enhancement Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Memory Enhancement Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Memory Enhancement Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Memory Enhancement Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Memory Enhancement Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Memory Enhancement Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Italy Memory Enhancement Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. France Memory Enhancement Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Memory Enhancement Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Memory Enhancement Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Memory Enhancement Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Memory Enhancement Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Memory Enhancement Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Memory Enhancement Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Memory Enhancement Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. South America Memory Enhancement Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Memory Enhancement Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Memory Enhancement Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Memory Enhancement Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Memory Enhancement Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Memory Enhancement Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Memory Enhancement Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Memory Enhancement Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Pfizer Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. UCB S.A.
  • 14.3. Takeda Pharmaceutical Company Limited
  • 14.4. SANOCHEMIA Pharmazeutika GmbH
  • 14.5. AbbVie Inc.
  • 14.6. Novartis AG
  • 14.7. Alkem Laboratories Ltd.
  • 14.8. Intas Pharmaceutical Ltd.
  • 14.9. Novartis AG
  • 14.10. Otsuka Holdings Co., Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer